Pre-Launch Activities and the Hatch-Waxman Act

Cheng, Avery & PLAIR · Volume 6, Issue 2 (2014)

The Hatch-Waxman Act of 1984 created the framework that governs the relationship between brand-name pharmaceutical companies and generic drug manufacturers in the United States. This article examines a specific and underexplored tension within that framework: the conflict between the FDA’s Pre-Launch Activities Importation Request (PLAIR) program and the patent protections that the Act was designed to preserve.

The PLAIR Program

The FDA’s PLAIR program allows generic drug manufacturers to import limited quantities of active pharmaceutical ingredients before patent expiration for bioequivalence testing and manufacturing preparation. The program is designed to enable generic drugs to reach the market more quickly after patent expiry, reducing the period during which consumers pay brand-name prices.

The Legal Tension

The authors identify a fundamental conflict: while the Hatch-Waxman Act’s research exemption permits certain pre-expiry activities related to regulatory approval, the scope of permitted pre-launch manufacturing activities remains unclear. The PLAIR program arguably extends beyond what the statute contemplates, creating potential patent infringement liability for generic manufacturers who rely on it.

Implications for Drug Pricing

The practical consequences are significant. If pre-launch manufacturing is restricted, generic drugs take longer to reach pharmacy shelves after patent expiry, extending the effective monopoly period for brand-name manufacturers. The article quantifies this delay and its cost impact on consumers and healthcare systems.

The Broader Patent-Competition Balance

The Hatch-Waxman Act represents one of the most significant legislative attempts to balance innovation incentives with competition in any industry. The Act created a system where brand-name manufacturers receive a defined period of market exclusivity in exchange for their research investment, after which generic competitors can enter the market through an abbreviated approval process. The PLAIR tension this article examines illustrates how the boundaries of that balance remain contested decades after the Act's passage.

Generic Access and Public Health

The stakes of this legal debate are concrete and, like the expansion of DNA databases, illustrate how technical advances can outpace the legal frameworks designed to govern them. The stakes are and measurable. Generic drugs save the U.S. healthcare system hundreds of billions of dollars annually. Each month of delay in generic market entry translates directly into higher drug costs for patients, insurers, and government programs. The article's analysis of how pre-launch manufacturing restrictions extend effective monopoly periods has been cited by organizations advocating for pharmaceutical patent reform and by generic drug manufacturers in regulatory proceedings.

The Hatch-Waxman framework continues to evolve through both legislation and litigation. The CREATES Act (2019) addressed another tactic used to delay generic entry: brand manufacturers restricting access to drug samples needed for bioequivalence testing. Each of these developments builds on the same fundamental tension between patent protection and generic competition that this article explores.

Frequently Asked Questions

What is the Hatch-Waxman Act?

The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, created the legal framework governing the relationship between brand-name and generic pharmaceutical manufacturers in the United States. It established the abbreviated new drug application (ANDA) process that enables generic drugs to reach the market.

What is the Bolar provision?

The Bolar provision, part of the Hatch-Waxman Act, allows generic drug manufacturers to use patented compounds for research and testing needed to obtain FDA approval before the patent expires. This exception enables generic manufacturers to have their products ready for market immediately upon patent expiration.

Why do generic drugs take time to reach the market after patent expiry?

Even with the Hatch-Waxman framework, generic manufacturers must complete bioequivalence testing, obtain FDA approval, and scale up manufacturing. The tensions between pre-launch manufacturing activities and patent protections, examined in this article, can add months to this timeline, extending the effective monopoly period for brand-name drugs.